Sponsored Content From Optimi Health Corp.*
👉Today’s alert is Optimi Health Corp. (NASDAQ: OPTH)👈
Optimi Health has quietly crossed an important line for psychedelic-sector investors: it is no longer just building infrastructure for a future market—it is a Nasdaq-listed, commercial-stage manufacturer already supplying psychedelic medicines into regulated patient care. The company began trading on the Nasdaq Capital Market under OPTH in May 2026 alongside an oversubscribed US$15 million public offering, and its 5 mg psilocybin capsules are now being prescribed in Australia for treatment-resistant depression. In August, Optimi added another potentially significant piece of financial firepower, establishing a discretionary equity facility that could provide access to up to $100 million.
Psychedelic-assisted therapy faces an unusual bottleneck: even where regulators permit patient access, providers still need standardized, pharmaceutical-grade products manufactured under strict quality controls, along with the permits, documentation and supply infrastructure required to move controlled substances between jurisdictions. Australia illustrates the opportunity and the challenge. MDMA and psilocybin remain unapproved therapeutic goods there, requiring authorized psychiatrists, ethics approvals and tightly regulated supply channels. Optimi is positioning itself on the manufacturing side of that bottleneck, producing validated MDMA and naturally derived psilocybin dosage forms under its Health Canada Drug Establishment Licence and supplying regulated therapeutic and research programs rather than relying solely on its own drug-development pipeline.
⚙️The Technicals
Ticker: $OPTH ( ▼ 1.59% )
Current float: ~4.65M shares
Company website: Optimi.net
Financial data summary: Finance.yahoo.com
Market data overview: Finviz.com
🚀Explosive Catalysts
Up to $100 Million Discretionary Equity Facility (August 14, 2026)
Optimi entered into a common-share purchase agreement with Seven Knots, LLC giving the company the right—but not the obligation—to sell up to $100 million of common shares over the life of the facility. Individual draws can reach as much as $2 million, subject to the agreement's conditions. For a company of Optimi's current size, that represents substantial potential access to growth capital for manufacturing and commercialization. The flip side is important: shares sold through the facility could meaningfully increase the share count, making dilution a key item for investors to monitor.
Third Commercial Psilocybin Shipment Reaches Australian Patients (June 29, 2026)
Optimi completed another export of its 5 mg naturally derived psilocybin capsules to Australia, marking its third commercial shipment since launching the product in September 2025. The shipment contained 1,000 capsules intended for treatment-resistant depression under Australia's Authorized Prescriber framework. This catalyst matters because it moves the Optimi story beyond regulatory approvals and manufacturing readiness toward repeat commercial supply: the company's product is actually moving through a regulated healthcare market and being prescribed to patients.
Optimi Health Corp. is a commercial-stage pharmaceutical manufacturer focused on GMP-grade psychedelic drug products for mental-health therapies. From its facilities in Princeton, British Columbia, the company manufactures validated MDMA and botanical psilocybin products and can supply both active pharmaceutical ingredients and finished dosage forms. Its products are being supplied to regulated therapeutic programs in Australia and through Canada's Special Access Program, while Optimi has also expanded into international clinical-research supply—including its first shipment of psilocybin to the United Kingdom for a planned Phase 2 clinical trial.
💎 Why This Company Stands Out
Optimi's biggest differentiator is its vertically integrated manufacturing model. Rather than functioning primarily as a biotech company betting on one proprietary clinical-stage molecule, Optimi controls cultivation, extraction, formulation and finished-dose manufacturing within its own licensed infrastructure. Its psilocybin program draws from a library of more than 200 mushroom genetics, and the company has produced naturally derived extract containing approximately 6% psilocybin. More importantly commercially, the same manufacturing platform can serve both regulated patients and clinical researchers: Optimi has supplied its 5 mg formulation into Australia's commercial framework while also exporting it for a planned UK Phase 2 study. That "picks-and-shovels" exposure to psychedelic medicine could allow Optimi to benefit as additional therapeutic programs emerge, though its future growth still depends heavily on regulation, adoption and successful commercialization.
Disclaimer: Sponsored Content
Trader's Incentive is a subsidiary of Parabolic Equities LLC (the “Publisher”). The Publisher received Six Thousand USD in cash via wire transfer from Bullish Media LLC ("Bullish Media") for a one day campaign beginning and ending on September Tenth Twenty Twenty Six, before the deduction of any applicable bank wire, PayPal, Wise, or electronic payment processing fees, in exchange for the publication and dissemination of the Information (as defined in the full disclaimer linked below). Bullish Media LLC, in turn, received funding acting on behalf of and with funding provided by the Issuer. All compensation received is strictly cash. Neither the Publisher nor Bullish Media LLC received any equity compensation, stock options, warrants, or securities-based consideration of any kind from the Issuer or any intermediary. Read the full disclaimer here:
Best regards,
The Trader’s Incentive Team